Too Much?
Folotyn is a chemotherapy drug indicated for patients suffering with peripheral T-cell lymphoma. The newly approved intravenous drug is manufactured by Allos Therapeutics.
The New York Times recently devoted an entire article to Folotyn. However, the article did not detail the efficacy or safety of the drug. Further, it did not share the story of a patient’s miraculous cure after being treated with Folotyn.
Instead, the article focused entirely on the price of Folotyn.
At $30,000 per month for treatment, Folotyn has attracted the attention of patient advocacy groups, oncologists and the health insurance industry.
No doubt Folotyn’s price will fuel more discussions on the costs of healthcare and the ethics of pharmaceutical pricing. However, in a broader sense, the drug’s price brings the topic of pricing back to the most basic marketing questions.
How much is too much?
And how much is too little?
